Anti-Human Fractalkine

Purified Recombinant Human Fractalkine (>98%)

This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.

The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.

Next Day Ambient

Neutralization: This antibody is useful for neutralization of Human FKN bioactivity. The antibody dose required to neutralize 50% (ND₅₀) of the biological activity of Human FKN (at 20 ng/ml) is 0.3 - 5 µg/ml.

Rabbit Anti-Human Fractalkine recognizes Human Fractalkine. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.

Fractalkine (FKN) is a transmembrane mucin-chemokine hybrid molecule expressed on activated endothelium¹ that mediates attachment and firm adhesion of T cells, monocytes and NK cells.² FKN plays an important proinflammatory role in rheumatoid arthritis (RA) pathogenesis as characterized by induction of synovial angiogenesis, chemotaxis, activation of monocytes and T cells as well as the stimulation of proliferation and synthesis of matrix degrading enzymes (matrix metalloproteinases, MMP) in synovial fibroblasts. Fractalkine thus may represent a novel target molecule for therapeutic intervention in RA.³ FKN is also an essential biomarker for predicting the prognosis of patients with colorectal cancer (CRC).⁴

1. Patel, DD. et al. (1998) J Exp Med. 188: 1413
2. Hwang, ST. et al. (1999) Eur J Immunol. 29: 2551
3. Muller, GA. et al. (2008) Z Rheumatol. 67: 424
4. Mori, M. et al. (2005) Int J Oncol. 26: 41